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2. ABBREVIATIONS 
 
 
 
ANOVA analysis of variance 
BT4C rat glioma model 
DAPI 4',6-diamidino-2-phenylindole 
DNA deoxyribonucleic acid 
DU 145 a human prostate cancer cell line 
EM estramustine 
EMBP estramustine binding protein 
EMBP-AB antibody against estramustine binding protein 
EMP estramustine phosphate 
FITC fluorescein isothiocyanate 
FMISO fluoromisonidazole 
G2/M a phase of cell cycle 
HSF hypoxia-specific factor 
MAP microtubulus-associated protein 
NOR Nitrogen ohne Radikal 
p53 nuclear phosphoprotein p 53 
PET positron emission tomography 
PMMA polymethylmethacrylate 
RBE relative biological efficiency 
R3327 a rat prostate cancer model 
RI radioiodine 
RI-EMBP-ABradioiodinated estramustine binding protein antibody 
RI-EMP Radioiodinated estramustine phosphate 
VEGF vascular endothelial growth factor 
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3. ABSTRACT 
 
Estramustine, a cytostatic drug used for treating advanced cancer of the prostate, 
has been shown to inhibit prostate cancer progression and also to increase the 
sensitivity of cancer cells to radiotherapy. The goals of this study were, first, to 
find out whether it is possible to use either estramustine or an antibody against 
estramustine binding protein as carrier molecules for bringing therapeutic 
radioisotopes into prostate cancer cells, and, secondly, to gain more 
understanding of the mechanisms behind the known radiosensitising effect of 
estramustine.  
 
Estramustine and estramustine binding protein antibody were labelled with 
iodine-125 to study the biodistribution of these substances in mice. In the first 
experiment, both of the substances accumulated in the prostate, but 
radioiodinated estramustine also showed affinity to the liver and the lungs. Since 
the radiolabelled antibody was found out to accumulate more selectively to the 
prostate, we studied its biodistribution in nude mice with DU-145 human 
prostate cancer implants. In this experiment, the prostate and the tumour 
accumulated more radioactivity than other organs, but we concluded that the 
difference in the dose of radiation compared to other organs was not sufficient 
for the radioiodinated antibody to be advocated as a carrier molecule for treating 
prostate cancer. 
 
Mice with similar DU-145 prostate cancer implants were then treated with 
estramustine and external beam irradiation, with and without neoadjuvant 
estramustine treatment. The tumours responded to the treatment as expected, 
showing the radiation potentiating effect of estramustine. In the third 
experiment, this effect was found without an increase in the amount of apoptosis 
in the tumour cells, despite previous suggestions to the contrary. In the fourth 
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experiment, we gave a similar treatment to the mice with DU-145 tumours. A 
reduction in proliferation was found in the groups treated with radiotherapy, and 
an increased amount of tumour hypoxia and tumour necrosis in the group treated 
with both neoadjuvant estramustine and radiation. This finding is contradictory 
to the suggestion that the radiation sensitising effect of estramustine could be 
attributed to its angiogenic activity. 
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4. INTRODUCTION 
 
The purpose of this study was to deepen our knowledge of the combined use of 
estramustine (EM) and radiotherapy for the treatment of prostate cancer. 
Prostate cancer is a common disease, with a high variability between subjects in 
its malignant potential. In many cases, the disease is an incidental finding with 
little or no clinical significance, because the slow progression of the tumour 
might not have caused any symptoms, nor mortality. In other cases, however, 
prostate cancer may be an aggressive malignant disease, which, if the initial 
treatment fails, lacks an effective cure and may lead to severe symptoms, 
metastasis, and death despite all treatment. In many cases, the methods of 
treatment available at the moment provide cure or significant regression of 
symptoms, but often at the cost of considerable side effects. 
 
Research on the treatment of prostate cancer may be considered to have three 
somewhat differing goals, corresponding to the different types or stages of the 
disease: 
1. To develop diagnostic tools for risk assessment of newly diagnosed 
prostate cancer in order to differentiate between high risk patients that 
benefit from active treatment in spite of its side effects, and low risk 
patients with whom refraining from treatment may be a better option, 
despite the risk of progressive disease. 
2. To improve or supplement existing treatment modalities for the more 
aggressive prostate cancer, in order to improve disease control and 
survival and diminish side effects. 
3. To develop treatment modalities for the advanced cases, where no 
effective treatment is available at the moment. 
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This is a study of one specific medical substance used in the treatment of 
prostate cancer, estramustine. This study was initiated primarily to look into the 
possibility of developing a targeting system for bringing a molecular radiation 
source into the substance of prostate cancer, and secondarily to give more 
insight into the mechanism of the known radiation sensitising effect of 
estramustine. The targeting system as well as radiosensitization could potentially 
be utilized in all types and stages of the disease mentioned above. 
 
The effectiveness and tolerability of molecular radioisotope treatment relies on 
targeting: the isotope must be retained in the organ to be treated, or, preferably, 
incorporated into the tumour cells, as close to nuclear DNA as possible. Thus, 
the development of suitable carrier molecules to take the isotopes selectively 
into the cancer cells is crucial. Both antibodies and other substances that have 
specific affinity to cancer cell targets have shown promising results in vitro and 
even in clinical trials. 
 
The radiosensitising effect of estramustine has been shown in many 
experimental studies and has been the subject of clinical trials as well. A 
considerable amount of research data is available on the mechanisms of the 
effect. This study adds to our knowledge on the subject, focusing on some 
specific, somewhat controversial issues. 
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5. REVIEW OF THE LITERATURE 
 
The following review will first briefly describe the prostate gland and the 
concept and treatment of cancer in general, then provide some more specific 
information on prostate cancer and its treatment options. Thereafter, the focus 
will be on EM and radiotherapy, and the radiosensitising effect of EM. 
 
 
5.1 The prostate gland – anatomy and function 
 
The prostate is an exocrine gland found only in the male. About four centimetres 
in diameter, it is the largest accessory gland of the male reproductive tract. The 
prostate is partly glandular and partly fibromuscular and is surrounded by a 
dense fascial sheath. The prostate is somewhat conical, with the base upwards 
and four surfaces (anterior, posterior, and two inferolateral surfaces) and the 
apex downwards. The lower part of the prostate faces the urogenital diaphragm, 
the urethral sphincter and levator ani muscles. The base is related to the neck of 
the urinary bladder, and the urethra enters the prostate in the base, near the 
anterior surface, and exits in the apex. The two ejaculatory ducts pass through 
the substance of the prostate to open into the prostatic urethra. The ejaculatory 
duct is formed by the union of the ductus deferens and the duct of the seminal 
vesicle on each side. The prostatic secretion is discharged by smooth muscle 
contraction into the urethra through 20 to 30 prostatic ducts that open into 
sinuses on each side of the posterior wall of prostatic urethra. The prostatic fluid 
constitutes up to one third of the semen. [1] 
 
The prostate is small at birth but enlarges at puberty. In most males it starts to 
enlarge in middle age, often leading to benign prostatic hyperplasia, which is a 
common cause of urinary obstruction. Cancer of the prostate gland is one of the 
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most common malignant tumours in men, microscopically detectable in about 
60% of men over 80 years of age. [1] 
 
 
5.2 Cancer 
 
Cancer is a generic term for a group of more than 100 diseases that can affect 
any part of the body. The defining feature of cancer is the rapid creation of 
abnormal cells which grow beyond their usual boundaries, and which can invade 
adjoining parts of the body and spread to other organs. The direct infiltration of 
cancer cells into adjacent tissue is referred to as invasion, and distinct tumours 
that arise from seeding of cancer cells via blood or lymphatic vessels are known 
as metastases. [2] 
 
Development of cancer 
The transformation from a normal cell into a malignant cell (cancer cell) is a 
multistage process, typically a progression from a pre-cancerous lesion to 
malignant tumours. The development of cancer may be initiated by external and 
genetic factors. The external factors include physical carcinogens such as 
radiation, chemical carcinogens such as tobacco smoke and biological 
carcinogens such as certain viral infections or microbial toxins. Ageing is also a 
factor in the development of cancer. The incidence of cancer rises dramatically 
with age, most likely due to risk accumulation over the life course combined 
with the tendency for cellular repair mechanisms to be less effective as a person 
grows older. Another distinct risk factor is lack of physical activity. [2] 
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Cancer mortality 
Metastases are the major cause of death from cancer; the primary tumour, often 
causing local and systemic symptoms, is a less common cause of mortality. 
From a total of 58 million deaths worldwide in 2005, cancer accounts for 7.6 
million (13%). The main types of cancer leading to overall cancer mortality 
among women are (in order of number of global deaths): breast, lung, stomach, 
colorectal and cervical cancer, and among men: lung, stomach, liver, colorectal, 
oesophagus and prostate cancer. [2] 
Treatment of cancer 
The four major types of treatment for cancer are surgery, radiotherapy, 
chemotherapy, and biologic therapies (according to [3]): 
 
Surgery may aim to radical or marginal excision of malignant tissue, but 
sometimes it is only possible to reduce tumour mass. Another important 
indication for surgery is to obtain tissue samples to establish the diagnosis and 
characterize the tumour, and to define the stage of the disease. A third indication 
is the palliation of symptoms caused by incurable cancer. 
 
Radiotherapy means treating disorders by submitting the affected tissue to 
ionising radiation. Most often it is used in combination with surgery to improve 
local control of the tumour, especially when the excision margins are not secure 
or when it has not been possible or desirable to remove the entire organ or 
compartment containing the tumour. In some cancers, radiotherapy alone may 
achieve cure or long-term remission and in others it is used in combination with 
other treatments. 
 
Chemotherapy refers to treatment by medication. In some cancers, total cure or 
long remission can be achieved by chemotherapy alone. In others, it is used to 
 15 
decrease the likelihood of recurrence or spreading after surgery or radiation 
(adjuvant chemotherapy), to make radiotherapy more effective (concurrent 
chemotherapy) or to shrink large tumours to operable size (neoadjuvant 
chemotherapy). In incurable or recurrent cancers chemotherapy may slow the 
growth and alleviate symptoms (palliative chemotherapy). 
  
Biologic therapy is sometimes called immunotherapy, biotherapy, or biological 
response modifier therapy. Biologic therapies use the body's immune system to 
fight cancer or to lessen the side effects of some cancer treatments. [3] 
Treatments utilizing antibodies may also be included in this category. 
 
 
5.3 Carcinoma of the prostate 
Risk factors 
About 80% of cases of prostate cancer occur in men over the age of 65. The 
prevalence of subclinical prostate cancer is high at all ages, but the lifetime risk 
of dying of prostate cancer is only 3%.  
Prostate cancer is more common in black men and those with a first-degree 
relative who has had prostate cancer. Obesity may increase mortality, and high 
intake of dairy products and calcium as well as red meat may slightly increase 
the risk of prostate cancer. Testosterone replacement therapy is considered a 
potential risk. [4, 5] 
 
Diagnosis and prediction of progression 
Patients with urinary symptoms or abnormal blood prostate specific antigen 
(PSA) levels are referred to examinations, which can lead to diagnosis of 
prostate cancer. Clinical findings may include a prostatic mass in rectal 
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examination or in transrectal ultrasonography. Multiple tissue samples are 
obtained under transrectal ultrasound guidance. The aggressiveness of prostate 
cancer varies from indolent, not requiring treatment, to aggressive, which may 
progress and metastasise despite treatment. The risk of progressive disease is 
estimated from tumour volume, aggressiveness, and extent of cancer. The 
primary measure of aggressiveness is the Gleason histological score: tumours 
scored 8-10 are considered the most aggressive, while those with scores under 6 
are potentially indolent. [3, 6, 7] 
 
The risk of progression, or recurrence after treatment, may be predicted in many 
ways, for example: 
 
Low risk:  PSA <10 ng/ml, Gleason score <6, 
and clinical stage T1c or T2a 
Intermediate risk: PSA > 10–20 ng/ml, Gleason score 7, 
or clinical stage T2b 
High risk:  PSA > 20 ng/ml, Gleason score 8–10, 
or clinical stage T2c 
 
The percentage of cancer positive core biopsies is considered an important risk 
factor, and various biochemical markers are being advocated as important tools 
in the assessment of the malignant potential of prostate cancer [8]. 
 
Current treatment options of prostate cancer 
The choice of treatment is based on the risk estimate, as well as other factors, 
such as patient preference, age and comorbidity. Radical prostatectomy is the 
most common curative treatment [5, 9]. The options include:  
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Watchful waiting / active surveillance, an active plan to postpone intervention 
of localized prostate cancer. The disease is monitored with digital rectal 
examination, ultrasonography, prostate biopsies and/or PSA blood tests. Active 
treatment is begun based on patient preference, symptoms, and clinical findings. 
The regimen causes no immediate side effects and has a low initial cost. Most 
patients, especially of low to intermediate risk, do not need other treatment and 
survive at least 10 years. The potential risks include the advancement of cancer, 
progression into an incurable disease, and patient anxiety. [3, 4, 6] 
 
Radical prostatectomy, the complete surgical removal of prostate gland with 
seminal vesicles, ampulla of vas, and sometimes pelvic lymph nodes. The 
operation may be done retropubically, perineally or laparoscopically. Efforts are 
made to preserve the nerves for erectile function. Radical surgery may eliminate 
cancer in some but not all cases. According to a randomised controlled trial, 
mortality from prostate cancer and metastasis is reduced compared with 
watchful waiting [10]. The operation is generally well tolerated. However, it 
requires hospitalisation and bears the risks of major surgery: perioperative death, 
cardiovascular complications, bleeding, urinary incontinence, urethral stricture, 
bladder neck contracture, and bowel and erectile dysfunction. In recent years, 
technological advances such as laparoscopy and robotic assistance have gained 
more popularity and may potentially improve the surgical outcome. [3, 11-13] 
 
External beam radiation therapy, ionising radiation from an external source 
applied in multiple doses over several weeks. Conformal radiotherapy uses 
three-dimensional planning systems to maximise dose to prostate cancer and to 
minimise it on adjacent tissue. In modern practice, external beam radiation is 
delivered by intensity-modulated radiotherapy (IMRT) or image guided 
radiotherapy (IGRT) [14]. 
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In some cases, external radiation may eliminate cancer. It is generally well 
tolerated. However, it does not remove the prostate gland and may not eradicate 
the cancer. The risk profile is somewhat more benign than with surgical 
treatment: incontinence, proctitis, diarrhoea, cystitis, erectile dysfunction, 
urethral stricture, bladder neck contracture, and rectal bleeding are the most 
common adverse effects, but their incidence has diminished with the new 
methods of delivery of radiation. Five to eight weeks of outpatient therapy is 
needed. Radiotherapy is contraindicated in the presence of an inflammatory 
bowel disease because of risk of bowel injury. [3, 15, 16] 
 
Brachytherapy is administered by temporarily placing radioactive implants into 
or in the proximity of the target tissue under anaesthesia using radiological 
guidance. External beam “boost” radiotherapy or androgen deprivation is 
sometimes recommended in combination. This treatment may also eliminate 
cancer and is generally well tolerated. It only requires a single outpatient 
session. As in external beam radiotherapy, it does not remove prostate gland and 
may not eradicate cancer. It may not be effective for larger prostate glands or 
more aggressive tumours and it is contraindicated in patients with prior 
transurethral resection of the prostate. The possible side effects include urinary 
retention, incontinence, impotence, cystitis or urethritis, and proctitis. [3, 8, 17] 
 
Androgen deprivation can be achieved either by oral or injected drugs or 
surgical removal of testicles to lower or block circulating androgens. The 
operation is smaller and avoids most of the risks of prostatectomy and 
radiotherapy. It typically lowers PSA levels and may slow cancer progression 
but does not remove the prostate and may not eradicate cancer. Side effects 
include gynaecomastia, impotence, diarrhoea, osteoporosis, lost libido, hot 
flushes, and “androgen deprivation syndrome” (depression, memory difficulties 
and fatigue). [3, 19, 19] 
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Chemotherapy, the use of cytostatic drugs in the treatment of prostate cancer, is 
mainly useful in the advanced stages of the disease [20]. Clinical trials have 
shown that docetaxel alone or in combination with estramustine improves the 
survival of patients with metastatic androgen independent prostate cancer [21, 
22]. Docetaxel is a taxane group cytostat. Estramustine alone has not been 
shown to improve survival. Other chemotherapeutic agents that are being 
investigated include vinca alkaloids (such as vinblastine and vinorelbine) and 
epothilones (such as ixabepilone and patupilone), but they have not improved 
survival. The effect of all of the above medications is based on anti-microtubule 
activity. [20] 
 
Cryoablation means destruction of cells through rapid freezing and thawing 
using transrectal guided placement of probes and injection of freezing and 
thawing gases into the prostate. In some cases, this may eliminate the cancer. It 
is generally well tolerated, avoids some of the operative risks and only requires a 
single outpatient session. However, it does not remove prostate gland and may 
not eradicate cancer, and has the risk of impotence, incontinence, scrotal 
oedema, pelvic pain, sloughed urethral tissue, prostatic abscess, urethrorectal 
fistula. No large long-term outcome reports are available on this treatment. [3, 
23, 24] 
 
 
5.4 Estramustine 
 
Estramustine phosphate (EMP), Estra-1,3,5(10)-triene-3,17-diol(17ß)-3[bis(2-
chloroethyl)carbamate]17-(dihydrogen-phosphate), disodium salt, hydrate, is a 
cytostatic pharmaceutical that has long been used for treatment of advanced, 
hormone refractory prostate cancer. Until recently, it was used as a second line 
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treatment against metastatic or advanced prostate cancer that did not respond to 
hormonal treatment or that had developed resistance to hormonal treatment after 
an initial response. [25-29] During the last decade EM has largely been replaced 
by docetaxel [30]. EM has also been used in clinical trials against malignant 
brain tumours [31-34]. In clinical experiments it is often used in combination 
with other chemotherapeutic agents, such as vinblastine and docetaxel [35-44], 
or with radiotherapy [31, 45]. In recent studies, treatment of hormone refractory 
prostate cancer with the combination of docetaxel and estramustine resulted in 
statistically significantly prolonged survival [21, 46]. The side effects of EM 
treatment include thromboembolic events, nausea, oedema, impotence and 
gynaecomastia [20, 47]. 
 
Structure 
Estramustine is a NOR-nitrogen mustard derivative of estradiol-17ß [48]. 
Estradiol-17-beta was earlier considered a potential hormonal treatment option 
for prostate cancer but it was later replaced by more complex oestrogen 
derivatives [49-51]. NOR-nitrogen mustard is used as an alkylating agent in 
chemical industry. It has been found to cause genomic damage, more effectively 
than nitrogen mustard does. [52, 53] NOR means Nitrogen ohne Radikal, 
nitrogen without methyl radical –CH3 [54]. 
 
 
 
Figure 1. Structure of estramustine phosphate (left) and estramustine (right). 
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Mechanism of anti-tumour effect 
Despite the presence of an alkylating agent and an oestrogen in EM, the anti 
tumour effect of EM is not based on alkylating or steroid (hormonal) activity 
[55]. It is believed to be due to direct and specific binding to tubulin, causing 
depolymerization of microtubules at high concentrations and, perhaps more 
importantly, stabilization of microtubule dynamics at much lower 
concentrations. Microtubules are responsible for the separation of the divided 
chromosomes in mitosis, and the impaired function of microtubules causes 
mitotic arrest at the transition from metaphase to anaphase (G2/M). The 
antimitotic effect of EM is reversible and it is not associated with genomic 
damage. Mitotic arrest may lead to cell death by apoptosis. Apoptosis may be an 
important mediator in the anti tumour action of EM. EM has been shown to 
cause low molecular weight (<1000 bp) DNA fragmentation and the 
morphological changes typical to apoptosis in glioma cells, in human gliomas 
and in prostate cancer cells. [34, 56-60] 
 
Other modes of action have been suggested, among them interaction with 
microtubulus-associated protein (MAP) [61-64] and inhibition of invasion by 
suppression of matrix metalloproteinase-2 and collagenase activity [65-67]. 
Both these actions and the induction of apoptosis may be consequences of the 
action on microtubules or MAP. 
Pharmacological properties 
Estramustine is administered perorally or intravenously as the water-soluble 
compound estramustine phosphate (EMP). EM is phosphorylated in the 17-beta 
position. EMP has no effect on cultured tumour cells in vitro, but in vivo it is 
rapidly dephosphorylated and hydroxylated into estramustine (EM) and further 
oxidized into estromustine [68-70], which has a dose-dependent antimitotic and 
antiproliferative effect on malignant cells. Such an effect has been described in 
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vitro and in vivo on many different cancer cell cultures, including prostate 
cancer [48, 71-76], glioblastoma [77-79], renal cell carcinoma [80], colon cancer 
[81-83] and breast cancer [84]. Estromustine, the predominant metabolite found 
in the circulation, is then metabolised into nitrogen mustard, estrone and 
estradiol and they are degraded and excreted so that prolonged use of EM does 
not lead to long-term accumulation of any of the substances [65, 66]. 
 
 
5.5 Radiosensitising effect of estramustine 
 
EM has been found to enhance the effect of irradiation in vitro on a variety of 
malignant cells, including prostate cancer (DU 145), breast cancer (MCF7), 
glioma (U-251, BT4C) and renal cell cancer (A498, CAKI 2) [80, 85-89]. In 
vivo experiments with DU-145 human prostate cancer cell xenografts implanted 
in nude mice, as well as those with Dunning R3327 prostate cancer and BT4C 
glioma cell xenografts in rats, have shown an increased sensitivity to irradiation 
when subjected to EM as compared to irradiation or EM therapy only [86, 89-
91]. In the 1994 experiment by Solveig Eklöv et al., DU 145 xenografts in nude 
mice responded with decreased tumour volume and increased necrotic content to 
combined treatment with estramustine and irradiation. Tumour growth was 
unaffected by estramustine alone and the radiation effect was statistically 
significantly higher than after radiation alone in tumour growth curves. The 
results were similar in the other studies with the above mentioned cell lines. 
Certain other malignant cells, including colon cancer (HT 29) and cervical 
cancer (HeLa S3) did not show significant radiosensitizing effect [88]. 
 
The radiosensitizing effect of estramustine, often combined with other 
chemotherapeutic agents, has been used in clinical trials in different settings for 
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the treatment of hormone refractory prostate cancer and glioma, often with 
promising results. [31, 32, 45, 92, 93] 
 
 
5.6 Estramustine binding protein 
 
One reason for the suitability of EM for treating prostate cancer is its tendency 
to accumulate in the prostate and prostate cancer. The reason for this is that EM 
binds not only to microtubules, but also to a protein called estramustine binding 
protein (EMBP). EMBP is found in high concentrations in cytoplasmic vesicles 
of epithelial cells of the prostate, constituting 18% of total protein in the cytosol 
of the rat ventral prostate epithelium. [94-96] It has also been detected in several 
other organs, including cerebral cortex, salivary glands, the thyroid gland, 
adrenal glands, seminal vesicles, epididymis, pancreas and kidney [94, 97] and 
in some, but not all, malignant cells including prostate cancer, breast cancer, 
melanoma, colon cancer, glioma, non-small cell lung cancer and renal cell 
cancer [82, 98-103]. 
 
The biological function of EMBP is not fully understood, but it is a secretory 
protein of the prostate and may have an immunosuppressive function [97, 98]. 
EMBP has a proteolytic effect on MAP, but not on tubulin [98]. The NOR-
nitrogen mustard component of EM is a necessity in binding to EMBP; estradiol 
and other steroids do not bind to the protein [95]. 
 
In the prostate, the concentration of EMBP is higher in the epithelium than in 
the stroma, and it is higher in benign prostatic hyperplasia than in prostate 
cancer [104, 105]. The appearance of EMBP in a tumour is not dependent on 
androgen or estrogen effect, and is not related to morphology or growth rate of 
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the tumour, but may be associated with androgen responsivity, androgen 
receptor content, anaplasia and metastatic potential [61, 106].  
 
Estramustine binding protein antibody 
 Antibodies against EMBP (EMBP-AB) accumulate in tissue that contains 
EMBP, and have been used to detect EMBP in vitro and in vivo [98, 103, 107]. 
 
 
5.7 Radiotherapy 
 
Radiotherapy means treating disorders by submitting the affected tissue to 
ionising radiation. 
 
Ionising radiation 
Radiation may be classified as directly or indirectly ionising. 
Directly ionising radiation includes neutrons and charged particles, such as 
electrons, protons, alpha particles (helium nucleus: two protons and two 
neutrons), mesons and heavy ions (nuclei of nitrogen, carbon, neon, argon etc.). 
Provided that the above-mentioned particles have sufficient kinetic energy, they 
can directly disrupt the atomic structure of the substance, which they traverse, 
and produce chemical and biological changes. Electromagnetic radiation (x-rays, 
gamma rays) is indirectly ionising. When absorbed to the substance they 
traverse, they give up energy to produce fast-moving charged particles, which in 
turn ionise other atoms of the absorbing substance and break chemical bonds. 
[108] 
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Biological effects of radiation 
Directly and indirectly ionising radiation is not to be confused with direct and 
indirect actions of radiation in the cell. 
Direct action is radiation damage caused directly to DNA, or another vital 
structure such as the cell membrane, by any form of directly or indirectly 
ionising radiation. It is the dominant process when using neutrons or alpha 
particles. Indirect action of radiation means that radiation interacts with other 
atoms or molecules in the cell, usually water, to produce free radicals, which are 
able to diffuse to critical targets. A free radical is an atom or a molecule carrying 
an unpaired orbital electron. An unpaired, or odd, orbital electron makes the 
atom highly reactive, enabling it to damage DNA by interacting with it. [108] 
 
 
5.8 Radiotherapy of prostate cancer with radioactive isotopes 
 
Iodine-125 is used as brachytherapy against prostate cancer. The long half-life 
of the isotope and the slow progression rate of the disease may be a cause for its 
clinical efficacy. Other advantages of a local iodine-125 radiation source are 
localized dose distribution, reduced development of radioresistance and reduced 
repopulation. [109-111] The Auger-electron radiation of I-125 has a short range. 
It is most effective when incorporated into DNA; this increases the biological 
effect of radiation by a factor of about ten as compared with extracellular 
radiation. The medium-energy beta-emitter I-131 has a longer range and more 
capacity to penetrate tissue, and the effect is little enhanced by proximity to 
DNA. [112, 113] Iodine-131 has been used in interesting experiments using, in a 
clinical trial, an antibody [114] or, in a xenograft model, a replication-defective 
adenovirus expressing the rat NIS gene (Ad-rNIS) [115, 116] as a vector to get 
therapeutic doses of I-131 into prostate cancer cells. In clinical use, systemically 
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administered radiolabelled antibodies have so far only proved useful in the 
treatment of haematological malignancies but not solid tumours [117-120]. 
 
Study of radioisotope treatment of prostate cancer is mainly focused on 
palliative treatment of painful bone metastases. Current treatment options 
include Re-186-HEDP (Rhenium 153 hydroxyethylidine diphoshonate) [121-
123], Sm-153-EDTMP (Samarium 153 ethylenediaminetetramethylene 
phosphonic acid), Ho-166 DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetramethylenephosphonate) [124-126], and Sr-89 (Strontium 89) [127-129]. 
These isotopes with the relevant carrier molecules (or, in the case of Strontium, 
Strontium chloride) have given good results in terms of pain palliation and 
tolerable side effects. 
 
 
5.9 Radiosensitization by estramustine  
 
There are a number of chemical agents that have been shown to increase the 
effectiveness of radiotherapy. The following paragraphs describe some of the 
key concepts of radiosensitization in relation to the mechanisms of 
radiosensitization by EM. 
 
Radiosensitivity and cell cycle 
 
The cell cycle of mammalian cells can be divided into phases: 
G0, cells that are out of the cell cycle, not dividing 
G1 (gap 1), the first phase after mitosis, when DNA is not being 
synthesized. The duration of this phase varies and causes the 
variation between the lenghth of the cell cycles of different types of 
cell. 
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S (synthesis), the phase during which DNA is synthesized to 
reduplicate it. 
G2 (gap 2), in which reduplicated DNA is segregated and 
condensed. 
M (mitosis), the separation of the reduplicated DNA and other cell 
structures and division of the cell into two identical cells, which 
enter the G1 phase. 
The sensitivity of cells to radiation varies during the cell cycle as follows: 
G0: low sensitivity. 
G1: sensitivity at the lowest in the beginning, then increases towards 
the end if duration of G1 is long enough. 
S: fairly sensitive in the beginning, then decreases towards the end. 
G2: low sensitivity at the beginning, increases towards the end, 
reaches maximum at transition to M. 
M: sensitivity at the highest in transition from G2 to M, decreases 
towards the end of M. 
The steepness of the radiation dose-response curve in G2/M is about 2,5 times 
that in late S. The reason for this difference is not entirely known. [108]  
 
The principal mechanism of the radiosensitizing effect of EM is the anti-
microtubule action of EM, causing the cell cycle to arrest in the G2/M phase, 
while cells in this phase are most sensitive to irradiation [130]. Treatment of 
prostate cancer cells with estramustine resulted in 95% of cells being in G2/M 
state (arrested metaphase with contracted chromosomes not aligned in the 
metaphase plane), and with no cells in anaphase [71]. The importance of this 
mechanism is underlined by the finding that cell lines that do not react to EM by 
arresting in metaphase are not sensitised to irradiation [88]. 
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Hypoxia in malignant tumours 
Solid malignant tumours are often hypoxic. Especially the core of the tumour 
may be too far from normally functioning blood vessels to receive adequate 
amounts of oxygen. Radiotherapy tends to further increase hypoxia by causing 
damage to microvasculature, although this effect may only be transitory due to 
the process of reoxygenation, which means improved oxygenation in the 
remaining hypoxic cancer cells after the successful deletion of well oxygenated 
cells by radiotherapy. Tumour hypoxia is a consequence of the way malignant 
tumours arise, whether primary or metastatic: they grow from a single, mutated 
normal cell into a solid tumour and, once their size exceeds the distance that 
oxygen is able to diffuse through their substance (about 100 µm), have to 
develop their own blood supply. They do this by stimulating the growth of cells 
from surrounding vessels into the tumour, a process known as angiogenesis. 
However, these newly formed blood vessels are irregular and tortuous, have 
arteriovenous shunts and blind ends, lack smooth muscle or nerves and have 
incomplete endothelium and basement membrane. As a result, blood flow is 
slow and irregular and the level of oxygen in most tumour cells is lower than in 
normal tissue. Hypoxic cells are less sensitive to irradiation because oxygen 
molecules, if present, react rapidly with free-radical damage produced by 
ionising radiation in the DNA, thereby making the damage irreversible and 
leading to cell death. [131] 
 
Some investigators suggest the induction of release of free oxygen radicals by 
EM as a mechanism of radiosensitisation [83, 89]. Another possible mechanism 
is increased tumour blood flow, shown in Dunning R 3327 rat prostate 
carcinoma model [91] and in BT4C rat glioma model [57]. EMP did not affect 
blood flow of normal brain tissue but increased the flow in the glioma. Increased 
tumour blood flow may relieve tumour hypoxia and thus potentiate the effect of 
irradiation. 
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Role of apoptosis 
Some of the DNA damage caused by irradiation may be repaired during the cell 
cycle, but if genomic damage persists, the cell cycle is arrested by suppressor 
genes. This, by mechanisms not known in full detail, leads to programmed cell 
death, apoptosis. The p53 suppressor gene is the most commonly mutated gene 
in human malignancies, leading to a defect in cell cycle control and decreased 
radiosensitivity of tumour cells. [132-134] However, other factors are involved, 
and radiation-induced apoptosis in prostate cancer cells is not dependent on over 
expression of mutant p53 [131]. 
 
Apoptosis might also have a role in radiosensitisation by EM, either by EM 
modulating the mechanisms that lead to apoptosis after irradiation, or by it 
having a direct additive effect. EM has been shown to cause apoptosis in cancer 
cells [34, 56-60]. It induced apoptosis by causing early DNA damage in glioma 
cells but not in normal brain tissue [34]. DNA damage has not been observed in 
all studies. However, mitotic arrest leads to apoptotic cell death even in the 
absence of direct damage to DNA [135-137]. 
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6. AIMS OF THE STUDY 
 
This study was based on certain special features of EMP: its ability to 
accumulate in the prostate and in cancer cells, the radiation sensitising effect, 
and the ability to cause apoptosis. Initially, the aim was to use EMP as a vehicle 
for transporting a radioactive isotope into cancer cells, where the isotope would 
function as an intracellular source of radiation, and EMP as a carrier molecule 
and as a radiation sensitiser. Secondly, we investigated the mechanisms of 
radiosensitization by EM. The aims of the study were as follows: 
 
I - To find out whether the known ability of EMP and EMBP-AB to accumulate 
in the prostate is present after radioiodination of the substances, and whether 
their biodistribution in terms of tissue uptake and clearance makes them suitable 
for use as carrier molecules for radioiodine into prostate cancer. 
 
II - To assess the uptake of a therapeutic dose of RI-EMBP-AB in prostate 
cancer in order to determine whether the dose of radioactivity absorbed by the 
tumour is sufficient to achieve therapeutic effects, and to compare the dose of 
radioactivity in the tumour with that in other organs to evaluate the safety of the 
treatment. 
 
III - To assess the role of apoptosis in the radiosensitizing effect of EM; to find 
out whether the EM-enhanced effect of radiation is mediated by an increased 
amount of apoptosis. 
 
IV - To determine the effect of EMP-treatment to the status of oxygenation in 
prostate cancer, when used either alone or as a radiosensitizing neoadjuvant 
treatment before and during radiotherapy. 
 31 
7. MATERIALS AND METHODS 
 
Four experiments were designed, corresponding to the aims of the study: 
Experiment I - The biodistribution of radioiodinated EMP and EMBP-AB and 
pure radioiodine was determined by injecting mice with the substances and 
measuring the radioactivity of different organs at time points. 
Experiment II – The first experiment was repeated with EMBP-AB, using nude 
mice with implanted tumours of DU-145 human prostate cancer. 
Experiment III – Similar nude mice with DU-145 tumours were irradiated with 
or without neoadjuvant EMP-treatment. Samples of the tumours and of the testes 
were analysed to determine the amount of apoptosis. 
Experiment IV – Nude mice with DU-145 tumours were irradiated with or 
without neoadjuvant EMP-treatment. The amount of hypoxia after the treatment 
was determined by measuring the accumulation of 18-fluoromisonidazole, 
injected at the end of the treatment, into the tumours and the testes. In addition, 
histological and immunohistochemical analyses were performed. 
 
The following chapter will describe the materials and methods used in the 
experiments in detail. 
 
 
7.1 Estramustine phosphate and estramustine binding protein 
antibody 
 
Estramustine phosphate, Estra-1,3,5(10)-triene-3,17-diol(17ß)-3[bis(2-
chloroethyl)carbamate]17-(dihydrogen-phosphate), disodium salt, hydrate 
(Estracyt ®) was obtained from Pharmacia-Upjohn, Lund, Sweden and from 
Pharmacia & Upjohn GmbH, Erlangen, Germany.  
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Clone A8-G11-C10-F9-B2 antibody against EMBP was obtained from 
Pharmacia-Upjohn, Lund, Sweden. The monoclonal antibody has been 
previously described in detail. Similar antibodies have been produced in other 
laboratories. The antibody adheres to its targets intracellularly. It has been 
shown to cross-react with human EMBP and produces a similar staining of 
purified rat EMBP and EMBP in DU 145 human prostate cancer cells. The 
antibody used in the experiment was tested by the supplier by western blotting, 
and it showed high affinity to the relevant epitopes. [107, 138] 
 
 
7.2 Radiolabelling 
 
Estramustine phosphate 
EMP was labelled using Iodogen® (1,3,4,6-tetrachloro-3!,6!-diphenyl 
glycoluril) (Pierce, Rockford, IL) as an oxidizing agent in phosphate buffer 0.15 
mol/l, pH 7.4. 1 mg EMP was iodinated using 75 MBq Na-I-125 (Amersham, 
Little Chalfont, UK). After 30 min incubation the supernatant was transferred 
from the iodination vessel, incubated for another 30 min and filtered with 2 ml 
of saline. 
 
Estramustine binding protein antibody 
In experiment I, EMBP-AB was iodinated with solid lactoperoxidase as follows: 
Lactoperoxidase suspension was first diluted 1:5 with acetate buffer 0.1 mol/l, 
pH 6.0. The iodination was started by adding 75 MBq of Na-I-125 and 20 "l of 
peroxide, 0.88 mmol/l, followed by two 10 "l additions of peroxide during 30 
min. After the incubation solid lactoperoxidase was centrifuged down and the 
supernatant was filtered with 2 ml of saline. 
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 The labelling was controlled with thin layer chromatography (ITLC Gelman 
Sciences, Ann Arbor, MI). The specimens were incubated against a high 
resolution photostimulable plate (Fuji-III, Fuji Co., Japan) and read by an image 
reader digiscan (Siemens Corp., Erlangen, Germany) using a linear fixed scale 
program. The solutions of RI-EMP and RI-EMBP-AB contained less than 1% 
and less than 5% of free RI, respectively. 
 
In experiment II, EMBP-AB was iodinated using lactoperoxidase sorbent (LPS) 
as follows: 10 "l of LPS suspension, 25 "l of stock EMBP-AB solution and 40 
"l of acetate buffer, 0.1 mol/l pH 6.0, were mixed. 2 mCi of Na I-125 was added 
to the mixture and iodination was started with 20 "l of hydrogen peroxide 
dilution (1:1000 of perhydrol). After iodination the precipitate was centrifuged 
and the supernatant diluted with isotonic sodiumchloride and filtered through a 
silver disc (Millipore). Tested by thin layer chromatography (ITLC Gelman 
Sciences, Ann Arbor, MI), the labelling efficiency was 60-70% and purity over 
90% after the filtering. 
 
Experiment II was repeated using I-131-labeled EMBP-AB. This time, labelling 
was performed like in experiment I, with solid lactoperoxidase. 
 
Fluoromisonidazole 
18
F-labelled fluoromisonidazole, 1H-1-(3-[
18
F]fluoro-2-hydroxypropyl)-2-
nitroimidazole ([18F]FMISO), was prepared in one step, starting from 1-(2’-
nitro-1’-imidazolyl)-2-O-tetrahydropyranyl-3-O-toluenesulfonyl-propanediol 
(NITTP) using an automatic fluorine-18 fluorodeoxyglucose (FDG) synthesis 
module made by IBA (Ion Beam Applications, Belgium). The synthesis 
procedure was based on the method by Lim & Berridge [136],
 
slightly modified 
by us. N.C.A. aqueous 
18
F-fluoride was transferred to the synthesis vessel 
containing 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo (8.8.8) hexacosane 
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(Kryptofix [2.2.2]) (13.5 mg) and Sodium carbonate (K2CO3) (1.7 mg) in 
acetonitrile/water (8:1). The solvents were evaporated under an argon-flow by 
adding 1 ml of acetonitrile (CH3CN) two times. Next, NITTP in 2 ml of CH3CN 
was added, and the reaction was performed at 100 °C during 10 min. 
Subsequently, 10 ml of diethyl ether was added, and the product was transferred 
through two silica Sep Pak cartridges (Waters, Milford, MA, USA) to a second 
vessel (in two 5-mL-portions). The ether was evaporated, and 2 ml of 1 N HCl 
was added to the residue for hydrolysis at 100 °C for 3 min. Then, 1 ml of 2 N 
NaOH was added to neutralize the solution. The solution was then transferred, 
through a C-18 Sep Pak cartridge (Waters), an Alumina Sep Pak cartridge 
(Waters) and a Millipore filter (Millipore Oy, Espoo, Finland) connected in 
series, to the product vial containing 1 ml of 1 N NaHCO3. Finally, the column 
was rinsed with 4 ml of 10%-ethanol and used subsequently for the animal 
experiment. No extra purification step was needed. [139, 140] 
 
The synthesis time was about 50 min and the radiochemical yield for the 
[18F]FMISO was 40% (End of Bombardment; EOB) on an average after a 
synthesis time of 96 min. The identity of the intermediates and the final product 
were confirmed by comparing the chromatograms with unlabelled reference 
materials. The radiochemical purity of the final product was over 97%, 
confirmed by thin layer chromatography (TLC) and high pressure liquid 
chromatography (HPLC). 
 
 
7.3 Experimental animals 
 
The study was approved by the ethical committee of the hospital and the 
committee for animal experiments. A total of about two hundred 6-12-week-old 
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male Balb/c mice were used in the experiments. Their weight ranged from 18 to 
22 g. The animals had free access to food and water. The mice in experiments 
III and IV were of the nude variant, with deficient cell-mediated immunity, to 
facilitate human xenograft transplantation. The nude mice were kept in an 
isolated room, in cages equipped with air filters. 
 
 
7.4 Tumour xenografts 
 
Human prostate cancer cells of the line DU 145 were cultured in modified 
Eagle's medium supplemented with 10% fetal bovine serum in a 5% CO2 
atmosphere and synchronised to an exponential growth phase. Two million cells 
(in II, 3.4 million cells) in 0.2 ml of saline were inoculated intracutaneously into 
each flank of the Balb/c nude mice. The tumours were allowed to grow for three 
to four weeks, reaching diameters of about 2 mm to 2 cm. Most mice had two 
tumours, one on each side. The larger one of the two tumours was taken as a 
specimen for tissue analysis. The tumour xenografts had no other visible effect 
on the animals. Three mice in IV had no tumour and were excluded from the 
study. 
 
To ascertain the effectiveness of the treatment, the changes in tumour size were 
measured. The volumes of tumours were calculated from the length, width and 
height of each tumour, measured with a calliper at the beginning of the treatment 
and 1 and 3 weeks thereafter. The relative size of the tumour was calculated by 
dividing the volume of the tumour at 1 and 3 weeks by the volume of the same 
tumour in the first measurement. 
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7.5 Determination of biodistribution 
 
In experiment I, RI-EMP, RI-EMBP-AB or pure iodine-125 (RI) was 
administered to each animal in an intravenous injection of 0.1 ml of saline. RI 
was used as a control to exclude the effect of free RI and RI dissociated from the 
other substances. The average dose of RI-EMP was 50 "g and that of RI-EMBP-
AB 100 "g. The activities of the syringes were measured before and after the 
injection, yielding an average injected activity of 150 kBq for RI-EMP, 75 kBq 
for EMBP-AB and 37 kBq for RI. The mice in RI-EMP and RI-EMBP-AB 
groups were decapitated 1, 3, 7, 15 or 31 h from the injection, while in the RI-
control group, only 1, 7 and 31 h periods were used. Three to four mice per time 
point were dissected in each group and specimens of 14 different organs were 
obtained. The specimens were weighed and their radioactivities were measured 
with a gamma counter (LKB 1282 Compugamma, Wallac Oy, Turku, Finland). 
 
In experiment II, the mice received an injection of RI-EMBP-AB. The average 
injected dose of I-125-EMBP-AB was 243 "Ci (9.00 MBq). In the group treated 
with I-131-EMBP-AB, the average injected dose was 19 "Ci (0.70 MBq). The 
mice were decapitated and dissected 4, 24 or 48 h from the injection and 
measured as in experiment I. 
 
In experiment IV, the mice were sacrificed three weeks from the beginning of 
the treatment. One hour before decapitation, about 5.6 - 7.4 MBq (150-200µCi) 
of [18F]FMISO was injected intraperitoneally to each animal. The activities of 
the syringes were measured before and after the injection. After decapitation, 
samples of the tumours, testes and hearts were weighed, and the activity of each 
sample was measured with the gamma counter as in I and II. Care was taken to 
include in the specimen a representative portion of all parts of the tumour, deep 
and superficial, excluding the entirely necrotic portion when present. The 
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decrease in the activity of 
18
F (T# = 109.8 min) during the time between the 
injection and the measurement of each sample was taken into account. To 
evaluate the uptake of [
18
F]FMISO, the decay-corrected activity of 
18
F in the 
samples was correlated with the injected activity of the individual animal and 
divided by the weight of the tissue sample, yielding the percentage of the 
injected activity per gram of tissue (%ID/g). The [
18
F]FMISO uptake ratio was 
obtained by dividing this value of a tissue sample with that of the heart from the 
same animal. 
 
 
7.6 Treatment with estramustine 
 
In experiments III and IV, estramustine phosphate was diluted with a solution 
containing 5% glucose into a concentration of 1 mg/ml. A daily dose of 0.2 mg 
estramustine phosphate (EMP) was injected intraperitoneally on 9 to 14 
consecutive days to each mouse randomised to get the treatment; the other mice 
received a daily injection of the same amount of the solution without EMP. 
 
 
7.7 Radiotherapy 
 
During the second week of estramustine therapy, the mice in groups R and ER 
were submitted to fractionated external beam radiotherapy (3 or 6 fractions of 6 
Gy within one or two weeks, total dose 18 and 36 Gy, respectively). The mice 
were placed in cylindrical polyethylene containers with inner diameter of 36 mm 
and wall thickness of 0.9 mm with conical ends so that the area to be treated 
rested congruently against the inner surface of the container. The containers 
were then placed into tightly fitting holes in a polymethylmetacrylate (PMMA) 
phantom to obtain adequate fixation of the mice and to get a sufficient build-up 
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layer for the superficial tumours. The phantom consisted of five cylindrical 
cone-ended holes to irradiate five mice at a time. The dimensions of the 
phantom were 29 cm ! 5 cm ! 6.5 cm (width, depth and height, respectively), 
which enabled the irradiation of five mice at a time with a treatment field size of 
28 cm ! 4.5 cm. Due to proper fixation and tranquility of the animals, the 
localization of the treatment areas was competent and sedation unnecessary. 
 
The mice were irradiated with a daily dose of 6 Gy with 6 MV photons 
produced by Varian Clinac 600 C linear accelerator (Varian Medical Systems 
Inc., Palo Alto, CA, USA). The field of radiation was limited to the caudal part 
of the animals, covering both of the tumours and the testes.  
 
 
7.8 Southern-blot analysis of apoptotic DNA fragmentation 
 
To assess the presence of apoptosis, samples of one tumour and one testis per 
mouse were examined. Tissue samples were snap-frozen in liquid nitrogen and 
stored at –70 °C until DNA isolation. Genomic DNA was extracted using the 
Apoptotic DNA Ladder Kit (Roche Molecular Biochemicals) according to the 
manufacturer’s instructions, with some modifications. Briefly, the carcinoma 
and testis samples were homogenised and incubated for 10 min at room 
temperature in a binding/lysis buffer (6 M guanidine-HCl, 10 mM urea, 10 mM 
Tris-HCl, 20% TritonX-100, pH 4.4). The samples were then mixed with 
isopropanol (final proportion of isopropanol 25%), loaded into polypropylene 
tubes and centrifuged for 1 min at 8000 rpm. The tubes were washed twice with 
washing buffer (20 mM NaCl, 2 mM Tris-HCl, pH 7.5), and the bound DNA 
was eluted from the tubes with 10 mM Tris, pH 8.5. Finally, the samples were 
incubated with RNase (2.5 µg/ml, Roche Molecular Biochemicals) for 20 min at 
room temperature. After quantification, the DNA samples were 3´-end-labeled 
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with digoxigenin-dideoxy-UTP (Dig-dd-UTP; Roche Molecular Biochemicals) 
by the terminal-transferase (Roche Molecular Biochemicals) reaction, subjected 
to electrophoresis on 2% agarose gels, and blotted onto nylon membranes 
overnight. Next day, the DNA was crosslinked to the membranes by UV 
irradiation. The membranes were then washed and blocked with 1% Blocking 
reagent (Roche Molecular Biochemicals) in maleic buffer (100 mmol/L maleic 
acid, 150 mmol/L NaCl, pH 7.5) for 30 min at room temperature. The 3´-end 
labelled DNA on the membranes was localised with alkaline phosphatase-
conjugated anti-digoxigenin antibody (Anti-Digoxigenin-AP; Roche Molecular 
Biochemicals), and the bound antibody was detected by the chemiluminescence 
reaction (CSPD, Roche Molecular Biochemicals). The x-ray films exposed to 
chemiluminescense were scanned with a tabletop scanner (Hewlett Packard 
ScanJet 6300C) and the digital image was analysed with Scion Image beta 4.0.2 
(Scion Corporation) analysis software. The digitised quantification of the low-
molecular-weight DNA fragments (< 1.3 kB) of the samples was expressed in 
relation to a standard amount (20 ng) of a commercial DNA marker (DNA Phix, 
Amersham). 
 
 
7.9 Histological and immunohistochemical analysis 
 
Pieces of tumours were snap-frozen in liquid nitrogen and cut to 5 µm for 
histological studying. After staining with hematoxylin and eosin, the specimens 
were evaluated for cellularity and necrosis by an experienced pathologist, 
unaware of the treatment groups of the samples. Monoclonal antibody PP-67 
against proliferating cell nuclear protein Ki-67 (Sigma, St Louis, MO) was used 
to assess proliferative capacity of the xenografts. For this purpose frozen 
sections were fixed with acetone at –20°C and the sections were exposed to 
fluorescein isothiocyanate (FITC)-coupled goat anti-mouse immunoglobulin 
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(Jackson Laboratories, West Grove, PA) for 30 min. After washing the 
specimens were exposed to DAPI (Riedel-de Haen, Hannover, Germany), to 
detect nuclei, and after washing were embedded and examined by using Leica 
Aristolan microscope equipped with appropriate filters. 
 
 
7.10 Calculation of the dose of radiation 
 
In experiments I and II, the effective half-lives of radioactivity were calculated 
by fitting the biodistribution data to an exponential curve. To calculate the 
absorbed dose of radiation in the tumour and in the prostate we used the 
effective half-lives, and the S-factors calculated earlier for the mouse testis, 
assuming the activity to be evenly distributed within a 100 mg sphere, with a 
radius of 3 mm. 
 
In experiments III and IV, the 6 Gy dose was calculated to the depth of 2.5 cm 
in the phantom which was the average depth of the tumours, at a source - 
phantom distance of 100 cm and a dose rate of 1.9 Gy/min in experiment III and 
3.8 Gy/min in experiment IV. The testicle dose in the average depth of 4 cm was 
5.6 to 5.8 Gy per fraction, depending on the position of the mouse. The variation 
of dose within the tumours was ± 5% or less. 
 
 
7.11 Statistical methods 
 
In IV, statistical analyses were performed using analysis of variance (ANOVA) 
to compare ratios (testis/heart and tumour/heart) between groups (O, E, R, ER). 
Paired t-test was used to compare ratios (testis/heart and tumour/heart) within 
groups for possible difference. ANOVA was also used to compare groups in 
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difference between ratios (difference between ratios testis/heart and 
tumour/heart). Pairwise comparisons in ANOVA were calculated comparing 
other groups to control (adjusted using Dunnett's method). P-value less than 0.05 
was considered as significant. The statistical analyses were carried out using 
SAS/STAT® software, Version 9.1.3 SP4 of the SAS System for Windows. 
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8. RESULTS 
 
8.1 Radiolabelling 
 
The labelling of EMP and EMBP with radioactive iodine was successful; only 
small amounts of free RI were present in the solutions. [18F]FMISO was 
prepared in about one hour with an average radiochemical yield of 40% decay-
corrected to end of bombardment. The radiochemical purity of the final product 
exceeded 97%, determined by radiochromatographic methods. 
 
 
8.2 Animals 
 
No side effects appeared after the injection in experiments I and II. The tail, which 
was the injection site, contained no significant radioactivity in any of the animals. In 
experiment III, the untreated mice gained about 10% of weight during the follow-
up. The mice in the six-day radiation groups had diarrhea starting on the fourth to 
fifth day of irradiation. They lost 25% of their weight rapidly and several of them 
died, leading to early decapitation of the rest of the mice in the six-day radiation 
groups, and to the conclusion that a 36 Gy total dose is too high in this setting. 
About half of the mice in the three-day radiation group had mild diarrhea, and they 
lost on average 10% of their weight but all survived. In experiment IV, no side 
effects were encountered. 
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8.3 Tumour size 
 
In sudy III, the size of an untreated tumour after four weeks was on average 8.96 
(+- 10,75) times the original size. Tumours treated with estramustine only were 
3.40 (+-3.58) times the original size. Those treated with radiation only (18 Gy) 
had grown to 1.21 (+-0.61) times and those treated with estramustine and 
radiation (18 Gy) had diminished to 0.46 (+-0.54) times the original size. The 
higher dose of radiation (36 Gy) was associated with high mortality and the 
tumour sizes in these groups were measured three weeks after the beginning of 
the trial: the sizes were 1.59 and 0.59 (+-0.13) times the original sizes for the 
radiation only and the estramustine and radiation groups, respectively. 
 
The relative size of the tumours in study IV increased constantly in the untreated 
group and, in this case, also in the group treated with estramustine. The groups 
treated by irradiation showed a decrease in the relative tumour size between 
weeks 1 and 3, with the combined treatment group decreasing more rapidly after 
an initial increase. 
 
 
8.4 Biodistribution 
 
Radioactive iodine 
In study I, RI was present in relatively high concentrations in almost all organs 1 
h after the injection: the prostate contained 11.9% ID/g, and most other organs 2 
to 4% ID/g. After that, the activities rapidly decreased. The prostate contained 
0.9% ID/g 7 h after the injection and most other organs less than 0.3%. The 
kidney, the lung and the gallbladder each contained about 1% ID/g after 31 h, 
while after 7 h, the gallbladder contained over 29.7% ID/g and the kidney and 
the lung 0.2% ID/g. 
 44 
 
RI was found to concentrate in the thyroid gland, 5.2% ID/g being present after 
7 h and 0.8% after 31 h from the injection. The thyroid gland also contained the 
most activity per weight in the RI-EMBP-AB group parenchymal organs. 7 h 
after the injection, the activity was 18.4% ID/g. The activity had decreased to 
0.1% after 31 h. In the RI-EMP group, the activity of the thyroid gland after 7 h 
and 31 h was 11.0% and 1.9% ID/g, respectively. 
 
Radioiodinated estramustine phosphate 
In study I, RI-EMP was found to accumulate in the liver and the gallbladder of 
the mouse. 1 h after the injection, the liver contained 21.4% of the injected dose 
(ID) / 1 g tissue. After 7 h, the liver contained 2.9% ID/g and the gallbladder 
332.0% ID/g. 31 h from the injection, the liver contained only 0.9% ID/g while 
the gallbladder still had 9.3% ID/g. The lung presented a diphasic accumulation 
of RI-EMP, containing 2.3% ID/g 7 h after the injection, while most other 
parenchymal organs contained 0.3-0.6% ID/g at the same time. The prostate was 
found to have more RI-EMP than most other organs at 1 to 7 h after the injection 
(6.4 to 2.6% ID/g, respectively). The activity in the prostate and in most other 
organs had practically disappeared after 15 h. The prostate/blood -ratio of the 
proportion of ID/weight of sample at 7 h was 3.3. The activities of most other 
organs were close to that of the blood. No organ seemed to retain significant 
activity longer than 31 h. 
 
Radioiodinated estramustine binding protein antibody 
RI-EMBP-AB accumulated in the prostate of the mouse. In study I it contained 
5.9 to 2.9% ID/g 1 and 7 h after the injection, respectively, while the liver 
contained 1.5 to 1.0% ID/g, as did most other parenchymal organs. The 
gallbladder contained 6.5% and 0.8% ID/g 7 h and 31h after the injection. 
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Prostate / blood ratio of activity at 7 h was 3.2. In study II, the prostate 
contained 2.4% ID/g after 4 h while the testis contained 0.95% ID/g.  
 
In study II, the amount of RI-EMBP-AB in the tumour graft (0.65% ID/g) was 
slightly higher than in blood (0.45% ID/g) and most other organs. The prostate 
contained 5.2 times and the tumour 1.4 times the amount in the blood at four 
hours. The organs which contained most RI-EMBP-AB at 4 h, the prostate, 
testis and the tumour, showed very short half-lives of radioactivity: 8.6, 10.4 and 
15.8 h, respectively. Half-lives in organs not accumulating much RI-EMBP 
were as follows: 37.6 h in the lung, 44.9 h in the blood, 50.6 h in the liver and 
94.7 h in the kidney. The doses of radiation absorbed by the prostate and the 
tumour, assuming the injected dose to be 1 mCi, were 1.81 and 0.92 cGy, 
respectively. The experiment was repeated with another group of Balb/c nude 
mice with similar DU-145 tumours, this time using I-131-labeled EMBP-AB. 
The prostate-blood ratio of activity was 4.5, but the tumour contained no more 
activity than the blood at 4 h. 
 
[18F]FMISO 
The distribution of [
18
F]FMISO was studied in experiment IV. In the control 
group testes the mean uptake value of [18F]FMISO was 1.14 ± 0.05 and that of 
tumours 1.73 ± 0.18. After treatment the values for testes in groups E, R and ER 
were 1.05 ± 0.19, 1.10 ± 0.15 and 1.33 ± 0.14, and for tumours 1.76 ± 0.38, 2.30 
± 0.68 and 2.64 ± 0.58, respectively. [18F]FMISO uptake ratio values of tumours 
were significantly higher than those of testes, being of statistical significance in 
all groups (p < 0.001) and the difference was significantly higher in groups R 
(p=0.019) and ER (p=0.012) than in the control group. 
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8.5 Apoptosis 
 
In study III, the relative amount of low-molecular-weight fragments of DNA 
after 24 h, consistent with apoptosis, was significantly higher in the DU 145 
tumours treated with radiation only or EMP only than in untreated tumours or 
those treated with the combination of EMP + radiation. In the testes, treatment 
with radiation only was associated with a significantly higher level of DNA-
fragmentation than in all other groups. 
 
After one week, the amount of DNA-fragmentation in the tumours of all groups 
was about the same, and thereafter the EMP group seemed to demonstrate 
higher levels, followed later by the untreated group. In the testes, the initial 
proneness to DNA-fragmentation in the radiation-treated group still persisted 18 
days after therapy, and the group treated with EMP + radiation showed rising 
levels from 1 week after treatment. 
 
 
8.6 Histology and Immunohistochemistry 
 
The results of the histological and immunohistochemical studies in experiment 
IV are shown in Table 2. There was more necrosis in the tumours of group ER 
than in the other groups and almost none in group O. The groups that had 
received radiotherapy (R and ER) had less mitoses and less proliferation (less 
Ki-67).  
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9. DISCUSSION 
 
9.1 Biodistribution of radioiodinated estramustine phosphate 
 
In study I, the distributions of RI-EMP and RI-EMBP-AB were relatively 
similar, except for the higher uptake of RI-EMP in the liver, gallbladder and 
lung. The distribution of RI, however, was totally different, which supports the 
assumption that the solutions did not contain excessive amounts of free iodine. 
The apparent uptake of RI-EMP and RI-EMBP-AB by the thyroid gland is 
possibly due to in vivo dehalogenation. The uptake of RI by the thyroid gland 
can easily be blocked by iodine. 
 
RI-EMP was found in the prostate in higher concentrations than in most other 
organs 7 h from the injection. The initial high concentration of RI-EMP in the 
liver decreased to the level of the prostate by 7 h. By that time, the concentration 
in the gallbladder had raised substantially: the gallbladder contained 3.3 times 
the injected activity per gram, which amounts to 3.3% of the injected activity in 
a gallbladder weighing 10 mg. The gallbladder retained a relatively high activity 
31 h after the injection. The hepatic uptake and biliary secretion of a steroid 
derivative is not surprising. The activity of the lung raised back to the level of 
3.6% ID/g 15 h after the injection, which equals the activity after 1 h. After that, 
the activity started to decrease again. The activity of the thyroid gland had 
decreased to 1.9% ID/g by 31 h. 
 
The prostate seems to be a target organ for RI-EMP, containing 2,6 % ID/g after 
7 h. However, the lung is found to have a roughly equal ability for uptake than 
the prostate, and to retain the radioactivity longer. The liver has a somewhat 
higher initial uptake, which decreases as RI-EMP is secreted in bile. 
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An earlier study on the distribution of tritiated EMP in rats had similar results: 
retention of activity in the prostate as compared to blood, and high accumulation 
into liver [28]. The accumulation of RI-EMP in the prostate and liver has also 
been observed in scintigraphic images of man [31]. 
 
In clinical use, the pulmonary and hepatic uptake and biliary secretion may not 
be significant, but if excessive toxicity or irradiation on these organs presents a 
problem, methods for local administration may have to be considered. 
Temporary surgical drainage of the biliary system could diminish irradiation of 
the bowel and other organs during the intestinal transit. The accumulation in the 
liver and lung may prove beneficial when RI-EMP is used to treat tumours in 
these organs.  
 
The absorbed radiation dose in the prostate was calculated as described earlier. 
We obtained 3.0 mGy/MBq for RI-EMP and 2.3 mGy/MBq for RI-EMBP-AB. 
The calculations are based on prostatic uptakes at 7 h (2.6% and 2.9% ID/g, 
respectively) and mean residence times (T 1/2 : ln 2) of 9.23 h and 6.35 h, 
respectively. This calculation does not take into account intracellular distribution 
and Auger-electrons. With Auger-electrons of I-125 the relative biological 
effectiveness (RBE) can be 7.9 for I-125-UdR [33], and thus also the absorbed 
dose can be higher in the range of one order of magnitude, because we assume 
RBE=1. 
 
The absorbed radiation dose with these tracers is feasible in view of their 
clinical use. When combined with the radiosensitizing effect of EMP, the 
radiation effect can be further enhanced. Whether the metabolites of RI-EMP 
have the same radiodensitising effect as those of EMP is not presently known 
and should be investigated. These studies are essential in determining the 
potential of RI-EMP in cancer treatment. 
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9.2 Biodistribution of radioiodinated estramustine binding protein 
antibody 
 
RI-EMBP-AB was found to accumulate in the prostate, which contained 2.9% 
ID/g after 7 h, the thyroid gland and the gallbladder. In an earlier study with rats 
receiving 10-50 "g of antibody L6, the proportion of activity at 6-24 h was 1.5-
0.7% ID/g in the liver, 1.6-1.2% ID/g in the lung and 1.4-0.8% ID/g in the 
kidney [33]. These figures are slightly higher than those of RI-EMBP-AB at 7-
31 h in our study: 0.7-0.1% ID/g in the liver, 1.0-0.1% ID/g in the lung and 0.9-
0.2% ID/g in the kidney. 
 
RI was found in much higher concentrations in the gallbladder after 7 h, but 
significantly less in the thyroid gland than RI-EMBP-AB. Antibodies may be 
removed from circulation through degradation; the rise of activity in the 
gallbladder is possibly due to RI freed in the process, or a result of in vivo 
dehalogenation. After 31 h, RI-EMBP-AB had disappeared from all organs. 
 
The accumulation of RI-EMBP-AB in the prostate was higher than that of 
antibody L6 in a heterotransplanted human tumour in a rat, even though this 
antibody showed excellent tumour uptake [34]. A study with antibody CE7 in 
mice demonstrated higher uptake in the liver, kidney and blood than that of RI-
EMBP-AB in our study [35]. In another study, radioiodinated antibody 17-1A 
was found to remain longer in most organs of nude mice than RI-EMBP-AB in 
our study, and the activity in the blood was about four times that in the liver 
[36]. 
 
Experiment I showed that RI-EMBP-AB is mostly taken up by the prostate. A 
known target for the antibody, the tumour was expected to accumulate activity 
at least as much as the prostate. Contrary to the expectations, experiment II 
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showed that the concentration of activity at its highest was not much higher in 
the tumour than in the blood. The dose of radiation in the prostate was two times 
higher than in the tumour. This is an interesting finding, as it means that the 
antibody could function as a carrier of radioiodine into the prostate but not into 
the tumour, both containing the relevant antigen. The reason for this could be a 
difference in the affinity of EMBP-AB to the antigen between the mouse 
prostate and the human tumour. Produced in mice against rat prostatic EMBP, 
the antibody has nevertheless been shown to have high affinity to human EMBP 
[107]. The relative affinities between species are not known and should be 
studied. Another explanation to our finding might be that the labelling of 
EMBP-AB affects its ability to be incorporated into cells in healthy tissue and 
tumour cells. 
 
In experiment II, the male reproductive glands and the tumour, containing high 
amounts of EMBP, initially accumulated RI-EMBP-AB but then lost it rapidly, 
while the descent of activity in other organs took place slower. The half-lives of 
activity in the blood and liver were about three-fold, and in the kidney about six-
fold, as compared with the tumour graft, while the concentrations of RI-EMBP-
AB in these organs at 4 h were only slightly lower than in the tumour. Thus 
most organs received doses of radioactivity comparable with that of the tumour, 
which would cause intolerable side effects when using I-125-EMBP-AB in 
therapeutic doses. Other agents should be studied to find better carrier 
substances for the treatment of hormone refractory prostate cancer, perhaps 
strontium-89, (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) and antibodies against 
prostate-specific antigen (PSA). 
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9.3 Apoptosis 
 
Studies on EMP-induced apoptosis have had follow-up times of 4 to 96 hours. 
This seems practical, since the plasma half-life of EMP in humans is 10-20 
hours. The possible long-term apoptotic effect of EMP has not been studied. In 
this study, we extended the follow-up time from 24 hours to 18 days from the 
end of all treatments to find out longer-term effects on apoptosis and to be able 
to verify the radiosensitising effect of EMP by tumour regression. The ability of 
EMP to potentate the effect of radiation on prostate cancer xenograft growth has 
been demonstrated earlier in a similar setting [86]. Our results are in accordance 
with the previous findings: the tumours that were treated with the combination 
of EMP and radiation tended to diminish in size, while radiation alone seemed 
only to retard growth and EMP alone had little effect. 
 
DNA fragmentation analysis was used as an indicator of apoptosis. In apoptosis, 
the DNA is divided by a process in the cell itself into fragments with a typical 
molecular weight distribution. This study uses the quantitative analysis of the 
typical molecular weight sequence. The measured values are compared to a 
standard sample, and the measurements in the charts can only be compared 
within the same chart, not so reliably between different charts and time points. 
For this reason, an untreated control group was included in the study. The 
amount of DNA-fragmentation 24 hours from the end of treatment was high in 
DU 145 tumours that were treated with either radiation or EMP alone. The 
amount was lower in tumours treated with the combination of EMP and 
irradiation than after a single-treatment regimen, although a greater diminution 
of tumours was noted after 2 weeks in the combined treatment group. This is in 
opposition to our hypothesis of an increase in apoptotic rate with the combined 
treatment, or an additive or potentiating effect on the separate apoptotic effects 
of radiotherapy and estramustine. Rather, both EMP and radiation seem to 
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prevent apoptosis caused by the other treatment modality. Therefore, the 
radiosensitising effect of EMP must be due to enhancement of some other 
mechanism of action of radiotherapy. Ischaemia due to damage on small blood 
vessels is a known effect of radiotherapy. Hypoxia, on the other hand, decreases 
radiosensitivity. EM has been shown to increase blood flow in tumours [17] and, 
theoretically, this could temporarily reverse radiation-induced ischaemia and 
return the cancer cells into a well-oxygenated, more radiosensitive state for the 
following irradiation sessions. This, however, is inconsistent with our finding of 
reduced apoptosis after the combined treatment. The mechanism of 
radiosensitisation may be based on other cellular level effects of radiation. As 
stated earlier, the mitotic arrest of the dividing cancer cells seems to play a role 
in radiosensitisation. 
 
The longer-term levels of DNA-fragmentation in all groups of tumours are 
rather similar, with a rise in the EMP-treated group after 2 weeks and the 
untreated group after 18 days. These results, showing no clear pattern, are 
probably of no greater significance. 
 
In the testis, radiotherapy had a significant increasing effect on DNA-
fragmentation from 24 hours to 18 days from treatment. EMP, while causing 
fragmentation in the tumours, did not have this effect on healthy testes. This is 
consistent with previous findings in malignant gliomas and healthy brain tissue 
[34]. In the testes, as in the tumours, the combination of EMP and radiation 
reversed the supposed apoptotic effect of both treatment modalities. In the 
longer-term follow-up, however, the testes treated with EMP + radiation showed 
DNA-fragmentation levels comparable with those of radiation. This is contrary 
to the observation in the tumours. The reason for this difference is not clear. 
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The amounts of DNA-fragmentation between 7 to 18 days from the end of 
treatment are comparable with the amounts after the first day and show 
considerable variation. This may be due to biological diversity in the tumours 
but may also have an impact on the long-term growth or regression of tumours. 
Long term effects on apoptosis should be taken into account in further studies 
and follow-up carried over a longer period than 1 to 3 days, even in cell culture 
and xenograft studies. 
 
 
9.4 Tumour hypoxia, proliferation and necrosis 
 
In experiment IV, most tumours had a necrotic centre despite 
neovascularisation, which was present superficially. In the untreated group 
(group O), the tumours had a relative [
18
F]FMISO uptake of 1.73 as compared 
with the heart, indicating tumour hypoxia. Tumours in groups O and E had more 
mitoses and more Ki-67, indicating stronger proliferation than in groups R and 
ER. The main finding of experiment IV was that as compared with tumours 
treated with EMP or radiation only, those in the group treated with both EMP 
and radiation showed more uptake of [
18
F]FMISO, indicating hypoxia. This 
group (ER) also had more necrosis in the histological samples. 
 
EMP concentrates less effectively in tissues with poor blood supply and it has a 
limited effect in the slowly dividing hypoxic cells. The effectiveness of EMP 
against cancer is believed to be mainly based on stabilising microtubule 
dynamics and preventing microtubule formation, causing mitotic arrest in the 
G2/M-phase of the cell cycle. [141, 142] Cells arrested in that phase are more 
sensitive to radiation. Because of the slow cell cycle, the radiosensitising effect 
is expected to be weaker in poorly oxygenated tissues. 
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The tissue specimen was taken from the viable layer of the tumour and no 
necrotic core was included. With the well-oxygenated superficial layer and the 
intermediate layer included and the central necrotic region excluded, the 
samples represent an average of the viable tumour in respect to tissue 
oxygenation. The trend towards increased tumour hypoxia after radiotherapy 
observed in this study and the increased amount of necrosis are attributable to 
radiation-induced injury to tissue and microvasculature. The radiation-induced 
hypoxia and necrosis in the tumours seemed to be accentuated by 
presensitization with EMP. The finding that the uptake of [
18
F]FMISO in the 
testes remained the same after the different treatment regimes suggests that EMP 
and irradiation do not induce as much damage to healthy tissue as to a malignant 
tumour. 
 
Another proposed explanation for the ability of EMP to sensitise tumours to 
radiation is that it increases their blood flow. This has been shown to occur in a 
rat brain glioma model [143]. By improving the oxygenation status of the 
intermediately oxygenated cells, EMP may widen the portion of the tumour with 
an oxygen tension sufficient for radiotherapy to be effective. EMP has been 
shown to counteract the anti-angiogenic effect of radiotherapy and to increase 
blood vessel size and density and the expression of VEGF [57, 143]. The 
presence of these phenomena in DU-145 cells was not addressed in our study 
and should be investigated by a different experimental approach. However, 
tumour blood flow does not necessarily directly correlate to the oxygenation 
status of all cells in a tumour; the increased flow may be directed mainly to the 
well vascularised portion of the tumour and leave the overall oxygenation status 
unchanged. In this study, estramustine alone did not slow down the growth of 
the tumours, had no effect on tumour proliferation and did not improve tumour 
oxygenation, but it did induce tumour necrosis when used either alone or in 
combination with irradiation. 
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10. CONCLUSION 
 
I - Radioiodinated estramustine phosphate has a biodistribution similar to non-
labelled estramustine phosphate. It accumulates in the prostate, the liver and the 
lung. The prostate-specific targeting of RI-EMP may promote its use as a 
combined radiating-radiation sensitising-cytotoxic agent against prostate cancer. 
 
The radioiodinated antibody against estramustine binding protein accumulates in 
the prostate, with no significant uptake in other organs. 
 
II - The uptake of 
125
I-EMBP-AB in DU-145 xenografts compared to most other 
organs is too low to make it feasible for targeted treatment of prostate cancer. 
 
III - Estramustine potentiates radiotherapy but not by enhancing radiation-
induced apoptosis. 
 
IV – Estramustine alone or in combination with radiotherapy was not shown to 
improve oxygenation of DU-145 xenografts. 
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11. SUMMARY 
 
The results of the study are summarized in the following tables: 
 
Table 1: 
Relative accumulation of radio iodinated estramustine (RI-EMP), radio 
iodinated estramustine binding protein antibody (RI-EMBP-AB) and radio 
iodine (RI) in different organs of the mouse. 
 
+ mild accumulation 
++ moderate accumulation 
+++ strong accumulation 
NT not tested 
 
 
 
 RI-
EMP 
RI- 
EMBP- 
AB 
RI 
Prostate +++ +++ + 
Testis + + + 
Kidney + + + 
Liver +++ + + 
Lung +++ + + 
Rectum ++ ++ +++ 
Heart + + + 
Spleen + + + 
Tumour NT + NT 
Bone + + + 
Blood + + + 
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Table 2: 
 
Relative effect of radiotherapy and estramustine on the mouse testis and DU-
145 human prostate cancer tumours implanted in nude mice. Roman numerals 
refer to experiments I–IV of this study.  
 
O no treatment 
E estramustine treatment 
R radiotherapy 
ER radiotherapy with neoadjuvant estramustine therapy 
 
 
o absent or minimal 
+ mild   
++ moderate   
+++ strong   
- mild regression 
- - moderate gegression 
- - - strong regression 
 
 
 
 
 
 O E R ER 
Tumour growth 
(III) 
++ + o - - 
Tumour necrosis 
(IV) 
o o o ++ 
Apoptosis (III) 
  Tumour 
  Testis 
24 h 
+ 
+ 
7 d 
++ 
+ 
24 h 
++ 
+ 
> 7 d 
++ 
+ 
24h 
++ 
++ 
> 7 d 
+ 
++ 
24 h 
+ 
+ 
> 7 d 
+ 
++ 
Proliferation (IV) 
  Mitosis 
  Ki 67 
 
+++ 
+++ 
 
+++ 
+++ 
 
++ 
+ 
 
++ 
+ 
Hypoxia (IV) 
  Tumour 
  Testis 
 
+ 
o 
 
+ 
o 
 
++ 
o 
 
+++ 
o 
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